Predictors of achieving and sustaining glycaemic control and weight loss with tirzepatide in individuals with type 2 diabetes and increased cardiovascular risk (SURPASS-4)

被引：0
|
作者：
Kahn, S. E. [1 ,2 ]
Del Prato, S. [3 ]
Pavo, I. [4 ]
Franco, D. R. [5 ]
Zheng, J. [4 ]
Nicolay, C. [4 ]
Hemmingway, A. [4 ]
Wiese, R. J. [4 ]
Pearson, E. R. [6 ]
机构：
[1] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[2] Univ Washington, Seattle, WA USA
[3] St Anna Sch Adv Studies, Pisa, Italy
[4] Eli Lilly & Co, Indianapolis, IN USA
[5] CPCLIN DASA Clin Res Ctr, Sao Paulo, Brazil
[6] Univ Dundee, Dundee, Scotland
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
757
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 50 条
  • [21] Sustainability of HbA1c control of tirzepatide vs insulin glargine in people with T2D and CV risk (SURPASS-4)
    Kahn, S.
    Del Prato, S.
    Pavo, I.
    Franco, D. R.
    Yang, Z.
    Hemmingway, A.
    Wiese, R. J.
    Pearson, E. R.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [22] ADA Presidents' Select Abstract: Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4
    Heerspink, Hiddo L.
    Sattar, Naveed
    Pavo, Imre
    Haupt, Axel
    Duffin, Kevin L.
    Yang, Zhengyu
    Wiese, Russell
    Tuttle, Katherine R.
    Cherney, David
    DIABETES, 2022, 71
  • [23] Effect of tirzepatide versus insulin degludec on glycaemic control captured with continuous glucose monitoring in patients with type 2 diabetes (SURPASS-3 CGM)
    Battelino, T.
    Bergenstal, R.
    Rodriguez, A.
    Lando, L. Fernandez
    Bray, R.
    Tong, Z.
    Brown, K.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 244 - 244
  • [24] Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
    Wing, Rena R.
    Lang, Wei
    Wadden, Thomas A.
    Safford, Monika
    Knowler, William C.
    Bertoni, Alain G.
    Hill, James O.
    Brancati, Frederick L.
    Peters, Anne
    Wagenknecht, Lynne
    DIABETES CARE, 2011, 34 (07) : 1481 - 1486
  • [25] Tirzepatide induces weight loss in patients with type 2 diabetes regardless of baseline BMI: a post hoc analysis of SURPASS-1 through SURPASS-5 studies
    Wilding, J. P. H.
    Kwan, A. Y. M.
    Maldonado, J. M.
    Wang, H.
    Rasouli, N.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S289 - S289
  • [26] PROs in Tirzepatide-Treated Adults with Type 2 Diabetes in SURPASS-1 to-6 by Age, Gender, BMI, and Weight Loss
    Boye, Kristina
    Thieu, Vivian
    Dong, Wenxiu
    Williamson, Suzanne E.
    Sapin, Helene
    DIABETES, 2024, 73
  • [27] An audit of glycaemic control and cardiovascular risk factors in patients with type 2 diabetes mellitus
    P. Downey
    L. O’Shea
    D. Dillon
    M. Corbett
    S. Sreenan
    Irish Journal of Medical Science, 2002, 171 (Suppl 5) : 11 - 12
  • [28] Orlistat promotes weight loss and improves glycaemic control in overweight patients with type 2 diabetes
    Hanefeld, M
    Platon, J
    Sachse, G
    DIABETOLOGIA, 2001, 44 : A231 - A231
  • [29] Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study
    Osonoi, Takeshi
    Oura, Tomonori
    Hirase, Tetsuaki
    DIABETES OBESITY & METABOLISM, 2024, 26 (01): : 126 - 134
  • [30] Weight loss surgery and cardiovascular risk and mortality in patients with type 2 diabetes
    Pournaras, Dimitri J.
    Welbourn, Richard
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (11): : 828 - 829
12345